advertisement
Abstract #9897 Published in IGR 5-3
Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension
Bron A; Chiambaretta F; Pouliquen P; Rigal D; Rouland JFJournal Français d'Ophtalmologie 2003; 26: 668-674
AIM: To evaluate the efficacy and safety of a single daily instillation of nonpreserved timolol in patients with chronic glaucoma or ocular hypertension previously treated with a twice-daily regimen of timolol 0.25 or 0.50%. PATIENTS AND METHODS: A prospective open clinical trial was undertaken by 220 ophthalmologists in 435 patients with chronic glaucoma or ocular hypertension controlled with twice-daily instillations of timolol 0.25 or 0.50%. In this population, the previous regimen was substituted with a single daily instillation of preservative-free timolol 0.25 or 0.50% for three months. The changes in intraocular pressure (IOP) were recorded, as well as local and systemic tolerance and patient compliance. RESULTS: It was found that 398 patients (93.6%) maintained stable IOP: in 92%, IOP increased no more than 2 mmHg. The mean IOP was 17.0 ± 2.2 mmHg at Day 0, 16.5 ± 2.4 mmHg at Days 28/42 and 16.6 ± 2.4 mmHg at Day 84. The proportion of patients with at least one ocular symptom upon instillation or at another time decreased (p < 0.0001 and p = 0.03, respectively). The proportion of conjunctival hyperemia reduced from 24.4 to 14.6% (p = 0.0002). The rate of folliculopapillar reactions and superficial punctate keratitis was halved (p = 0.005 and p = 0.02, respectively). CONCLUSION: During this study in daily practice, the switch from a twice-daily regimen of timolol to a once-daily application maintained stable IOP with a notable improvement in tolerance. LA: French
Dr. A. Bron, Service d'Ophtalmologie, CHU de Dijon, Hôpital Général, 3, rue du Faubourg Raines, BP 1519, 21033 Dijon Cedex, France. Alain.bron@CHU-Dijon.fr
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
